Neil Kumar - Feb 10, 2021 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
CEO and President, Director
Signature
/s/Brian C. Stephenson, Attorney-in-fact
Stock symbol
BBIO
Transactions as of
Feb 10, 2021
Transactions value $
$0
Form type
4
Date filed
2/14/2023, 04:25 PM
Next filing
May 18, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Award $0 +625K $0.00 625K Feb 10, 2023 Common Stock 625K $11.41 Direct F1
transaction BBIO Restricted Stock Units Award $0 +537K $0.00 537K Feb 10, 2023 Common Stock 537K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option vest and become exercisable in 48 equal monthly installments after February 10, 2023, such that all of the shares subject to the option shall be vested and exercisable on February 10, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSU's have no expiration date.